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Nar Farsi (Eczema) is a very common skin inflammatory disorder. Its prevalence varies according to age groups and country 
to country. The Unani system of medicine offers its successful management. In this study, efficacy and safety of a topical 
Unani formulation was assessed and compared with a standard drug. A prospective, non inferiority, randomized, active 
controlled and parallel group study was designed to study 60 participants of eczema (30 participants in each group). 
The Unani formulation Marham Safeda Kafoori was studied as a test drug for 6 weeks versus allopathic medicine Clobetasol 
Propionate in the study. The study findings suggested that the Unani formulation was non inferior to Clobetasol Propionate 
in terms of percentage of reduction in itching, oozing, exudation, erythema, lichenification and cracking at 6 weeks of 
treatment. It was observed that the difference of the mean±SD of SASSAD Score was measured as 12.83±4.76 and 
14.13±5.27 in test and control groups respectively. The result was analysed as per protocol and it was found that the efficacy 
of the Unani formulation was statistically significant (p<0.001). This study concluded that the Unani formulation was safe 
and effective in the treatment of eczema. 
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Eczema is a very common skin disorder in all age 
groups. It is characterized by a changeable intensity of 
itching and soreness and in variable degrees a range 
of signs including dryness, erythema, excoriation, 
exudation, fissuring, hyperkeratosis, lichenification, 
papulation, scaling and vesiculation1. The prevalence 
of this disease lies between 2% and 3% of 
all dermatology consultation2. Contact dermatitis 
accounts for 4% to 7% of all patients presenting to the 
dermatology clinics3. Hand and foot eczema is the 
commonest type of contact dermatitis. The teenagers 
suffer from this disease in proportion to 15.2% and in 
the case of adults the prevalence is higher and can 
reach 18.6%. There is a lifetime risk of developing 
hand eczema of 20%4. In the Unani system of 
medicine, the pathogenesis of this disease is humoral 
in nature. Any derangement in quality and quantity of 
any of the four humours bilious (safra), melancholic 
(sauda), phlegmatic (balgham) and sanguine (dam) 
may lead to the development of this disease5-9,  
Contact dermatitis can be divided into two types: 
irritant contact dermatitis and allergic contact 
dermatitis. The presentations are similar in each type. 
Irritant contact dermatitis is the result of direct 
damage to the skin by an allergen4. So its onset can be 
rapid, within minutes of being exposed. Whereas 
allergic contact dermatitis is due to a delayed 
hypersensitivity reaction, which present generally 
after 48 h of exposure to allergens10. 
Eczema is a disability disease. It produces socio-
economic problems for the patients. The patients 
having any forms of eczema may have sleeplessness, 
anxiety, personality disorder and inability to perform 
daily routine work. In conclusion, this ailment 
disrupts the quality of life of the patients11-13. The 
diagnosis of this disease is simple. However, 
detection of allergens and their avoidance are very 
difficult. In conventional medicine therapeutics for 
topical as well as systemic use are available. But they 
have limitations. Non-response to the therapy, 
recurrence of the disease, side effects of the drugs and 
complete avoidance of allergens are the prominent 
limitations, which leads to a quest for a newer and 
better drug. These circumstances have attracted 
renewed interest in the Unani system of medicine. 
Unani system of medicine offers treatment for skin 
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disorders and adopts a holistic approach to provide 
complete cure to any health problem. The Unani 
pharmacopoeia contains many formulations for the 
treatment of eczema. They have been documented 
after a long time of clinical practice. In this study, we 
selected the formulation Marham Safeda Kafoori, an 
animo-herbo-mineral formulation from the Unani 
pharmacopoeia Qarabadeen Azam wa Akmal14,15. 
This formulation has been indicated for eczema, but it 
has never been studied in any clinical study to 
document its efficacy and safety so that its 
effectiveness can be established to be used as a potent 
drug for eczema in clinical practice. 
 
Materials and Methods 
This study was conducted with 60 participants of 
eczema at Central Research Institute of Unani 
Medicine (CRIUM), Hyderabad during June 2018 and 
July 2019. The participants were recruited from the 
outdoor patient department of CRIUM hospital. This 
study was registered in the Clinical Trial Registry-
India (CTRI) under registration No. CTRI/2017/ 
12/010957 dated 17/10/2017 after Institutional Ethics 
Committee approval of the protocol, written informed 
consent form and case record form of the study  
(EC Ref. No.38-18/2015-16/CRIUM/Hyd/IEC/05/M, 
dated 07.08.2017). 
 
Sample size estimation 
The total sample size of this study was 75 
participants including expected 25% dropout. The 
sample size of 60 participants in this academic study 
was taken empirically. This study was designed as 
non-inferiority, randomized, single-blind (assessor 
blinded), parallel group and active-controlled. 
Participants of any sex in the age group of 18 to 65 
years having any 3 clinical features itching, erythema, 
excoriation, scaling, hyperpigmentation, burning 
sensation and lichenification were included in the 
study. The participants having concomitant therapy, 
those who had comorbid diseases or those suffering 
from diabetes mellitus, hypertension, hepatic 
disorders and pregnant and lactating women were not 
included in the study.  
 
Enrollment of participants 
The first participant was enrolled in the study after 
its registration in the Clinical Trial Registry-India. 
The participants fulfilling the inclusion and exclusion 
criteria were given a Participant Information Sheet 
(PIS) to go through its contents and get clarified if 
there was any query and signed the informed consent 
form to participate in the study. The participants were 
randomized into test group (n=30) and control group 
(n=30) at a ratio of 1:1 as per the pre-specified 
scheme of block randomization generated by a 
computer (block of 4 participants). The sequence of 
the block was concealed in sequentially numbered, 
opaque, sealed envelopes. In total, 112 participants 
were screened. But 25 participants did not fulfill the 
inclusion and exclusion criteria and 5 participants did 
not provide consent to participate in the study. 82 
participants was enrolled into the study. 60 
participants could complete the duration of protocol 
therapy of 6 weeks. The Figure 1 shows the flow of 
the participants in the clinical trial. 
 
Intervention 
We selected Marham Safeda Kafoori (MSK), a 
Unani pharmacopeial formulation, constituted of 
animo-herbo-mineral single drugs for its safety and 
efficacy study. The ingredients of the formulation 
MSK has been displayed in Table 1. All the 
ingredients were identified by the experts in the 
Pharmacy Section and Survey of Medicinal Plant Unit 
 
 
Fig. 1 — CONSORT flow diagram of the participants in the 
clinical trial 
 
Table 1 — The composition of MSK 
S. N. Ingredients Weight 
1 Mom Safaid (Pure wax) 4.50 g 
2 Raughan-e-Gul (Rosa damascena, Mill) 22.5 g 
3 Safedab (Zinc oxide) 4.50 g 
4 Murdar Sang (Lead oxide) 4.50 g 
5 Safedi Baiza (Egg albumin) 40.0 g 








(SMPU) of the institute. The Unani formulation was 
prepared in a single batch as per standard operating 
procedure mentioned in Unani pharmacopoeia14. 
Clobetasol propionate was used as a controlled drug 
in the dosage form of ointment for local application16. 
 
Assessment of efficacy and safety 
The primary endpoint of the study was either 
completion of 6 weeks of treatment or cure of the 
disease before 6 weeks of treatment. The efficacy of 
the formulation was assessed clinically. The severity 
of eczema was assessed by SASSAD (Six Area Six 
Signs of Atopic Dermatitis) Score (score: 0=Absent, 
1=Mild, 2=Moderate, 3=Severe)17. The improvement 
in subjective parameters itching, dryness, erythema, 
oozing/exudation, scaling, excoriation and 
lichenification was recorded in a SASSAD score at 
baseline, every follow ups and at 6 weeks of the 
treatment. The photographs of every lesion of the 
participants were taken at baseline and post treatment. 
Local and systemic safety was assessed during the 
course of the therapy. Haematological and 
biochemical parameters were observed at baseline and 
after 6-week treatment. 
 
Statistical analysis 
In the present study, the descriptive and inferential 
statistical analysis had been carried out. The results of 
continuous and categorical data were presented in 
mean±SD and frequency (percentage) respectively. 
Student t-test (two-tailed, dependent) was used to find 
the statistical significance of study parameters. p<0.05 
was considered for statistical significance. The 
statistical software SPSS 15.0 had been used for the 
analysis of data. The graphs and tables had been 
generated using Microsoft Excel 2016. Good Clinical 
Practice (GCP) guidelines had been followed for data 
collection.  
 
Observations and Results 
This study was designed as non-inferior, 
randomized and active-controlled. We conducted this 
study to assess the efficacy and safety of the Unani 
pharmacopeial formulation MSK in the management 
of eczema. The clinical and demographic profiles of 
the participants are given in Table 2. The baseline 
characteristics of the participants were almost similar 
in both groups. The mean age of the participants was 
39.6 years and 44.06 years in the test and control 
groups respectively. There were 11 males and  
19 females in each group. The average chronicity of 
the illness was 2.6 months and 2.8 months in the  
test and control groups respectively. We observed 
majority of the participants in the age group  
31-40 years i.e., 15 participants. In addition, the 
temperament of the participants was balghami in 34 
(56.7%), damvi in 16 (26.7%), safravi in 6 (10%)  
and saudavi in 4 (6.7%) participants. 17 (28.3%) 
participants in the test group and 12 (20%) 
participants in the control group belonged to the lower 
middle class of socio-economic status.  
This study showed that the participants in  
the test group had itching (83.3%), papules (60%), 
erythema (76.7%), dryness (83%), exudation (73.3%), 
cracking (43.3%), localize swelling (60%) and 
lichenification (63.3%) whereas the participants in the 
control group had itching (76.7%), papules (60%), 
erythema (93.3%), dryness (90%), exudation (76.7%), 
cracking (56.7%), localized swelling (70%) and 
lichenification (46.7%). In this study the Unani 
formulation showed improvement (test group vs. 
control group) in itching (60% vs. 76.7%), papules 
(100% vs. 86.7%), erythema (86.7% vs. 86.7%), 
dryness (100% vs. 100%), exudation (96% vs. 90%), 
cracking (76.6% vs. 86.7%), localize swelling (73.4% 
vs. 93.4%) and lichenification (73.3% vs. 73.4%). The 
Tables 3-6 display the improvement in itching, 
Table 3 — Effect of the formulations on Itching 
Itching  Test group (n=30) Control group (n=30) 
Baseline Post Treatment % Changes Baseline Post Treatment % Changes 
Absent 0 (0%) 18 (60%) 60.0% 0 (0%) 23 (76.7%) 76.7% 
Mild 0 (0%) 12 (40%) 40.0% 0 (0%) 7 (23.3%) 23.3% 
Moderate 5 (16.7%) 0 (0%) -16.7% 7 (23.3%) 0 (0%) -23.3% 
Severe 25 (83.3%) 0 (0%) -83.3% 23 (76.7%) 0 (0%) -76.7% 
Total 30 (100%) 30 (100%) - 30 (100%) 30 (100%) - 
 
Table 2 — Demographic profiles of the participants 
S. N. Variables Test group Control group 
1 No of participants,  30 30 
2 Average age (years) 39.6 44.06 
3 Male, n (%) 11 (36.7) 11(36.7) 
4 Female, n (%) 19 (66.3) 19 (66.3) 
5 Average chronicity  2.6 months 2.8 months 
6 Positive family history, n 3 2 
7 Co-morbidity, n 2 4 
 




erythema, exudation, and lichenification after  
6 weeks of treatment with test formulation and  
control drug. 
Assessment of the efficacy of the Unani 
formulation was made on the basis of reduction in 
cumulative score assigned for the signs and symptoms 
based on SASSAD SCALE (Six Area Six Signs of 
Atopic Dermatitis) at 6 weeks of treatment compared 
to baseline. The mean (±SD) SASSAD Score in the 
participants of the test group (n=30) at baseline was 
13.43±4.35 whereas 14.50±5.36 in the control group. 
It was observed that after 6 weeks of treatment the 
mean (±SD) SASSAD Score was reduced to 
0.60±2.02 and 0.37±0.66 in the test and control 
groups respectively. The difference of the mean 
(±SD) SASSAD Score was measured 12.83±4.76 and 
14.13±5.27 in the test and control groups respectively. 
The mean (±SD) SASSAD Score at baseline and post 
treatment in the test and control groups has been 
displayed in Table 7. The result was analysed as per 
protocol criteria and it was found that the reduction in 
mean (±SD) SASSAD Score post treatment was 
statistically significant (p<0.001) when compared to 
baseline in the test and control groups. When the 
reduction in mean (±SD) SASSAD score was 
compared inter group, the difference was not 
statistically significant. However, the Unani 
formulation was found clinically effective in reducing 
the symptoms and signs of eczema. The efficacy of 
the Unani formulation was comparable to the 
Table 4 — Effect of the formulations on erythema 
Erythema Test group (n=30) Control group (n=30) 
Baseline Post Treatment % Changes Baseline Post Treatment % Changes 
Absent 0 (0%) 26 (86.7%) 86.7% 0 (0%) 26 (86.7%) 86.7% 
Mild 0 (0%) 4 (13.3%) 13.3% 0 (0%) 4 (13.3%) 13.3% 
Moderate 7 (23.3%) 0 (0%) -23.3% 2 (6.7%) 0 (0%) -6.7% 
Severe 23 (76.7%) 0 (0%) -76.7% 28 (93.3%) 0 (0%) -93.3 
Total 30 (100%) 30 (100%) - 30 (100%) 30 (100%) - 
 
Table 5 — Effect of the formulations on exudation 
Exudation  Test group (n=30) Control group (n=30) 
Baseline Post Treatment % Changes Baseline Post Treatment % Changes 
Absent 0 (0%) 29 (96.7%) 96.7% 2 (6.7%) 29 (96.7%) 90% 
Mild 6 (20%) 1 (3.3%) -16.4% 5 (16.7%) 1 (3.3%) 3.3% 
Moderate 22 (73.3%) 0 (0%) -73.3 23 (76.7%) 0 (0%) -76% 
Severe 2 (6.7%) 0 (0%) -6.7 0 (0%) 0 (0%) - 
Total 30 (100%) 30 (100%) - 30 (100%) 30 (100%) - 
 
Table 6 — Effect of the formulations on lichenification 
Lichenification Test group (n=30) Control group (n=30) 
Baseline Post Treatment % Changes Baseline Post Treatment % Changes 
Absent 8 (26.7%) 30 (100%) 73.3% 4 (13.3%) 26 (86.7%) 73.4% 
Mild 14 (46.7%) 0 (0%) -46.7% 19 (63.3%) 4 (13.3%) -50.0% 
Moderate 8 (26.7%) 0 (0%) -26.7% 7 (23.3%) 0 (0%) -23.30 
Severe 0 (0%) 0 (0%) - 0 (0%) 0 (0%) - 
Total 30 (100%) 30 (100%) - 30 (100%) 30 (100%) - 
 
Table 7 — Effect of the formulations on SASSAD Score 
 Test group (n=30) Control group (n=30) 
Min-Max Mean±SD Mean 
difference±SD 
p-value Min-Max Mean±SD Mean 
difference±SD 
p-value 
Baseline 9-26 14.50±5.36 - - 9-28 13.43±4.35 - - 
F1 8-24 13.50±4.9 1.00±0.95 <.001 8-24 12.47±4.01 0.967±0.1 <001 
F2 5-2 11.17±4.38 3.33±1.75 <001 6-22 10.27±3.9 3.167±1.42 <001 
F3 4-16 8.20±2.91 6.30±2.88 <001 4-16 7.57±2.83 5.867±1.96 <001 
F4 3-12 5.77±2.45 8.73±3.05 <001 2-12 5.20±1.96 8.233±2.61 <001 
F5 0-8 3.67±2.45 10.83±3.95 <001 0-6 3.13±1.68 10.300±3.56 <001 
Post Treatment 0-2 0.37±0.7 14.13±5.27 <001 0-11 0.60±2.08 12.833±4.76 <001 
 




controlled drug clobetasol propionate. In our study the 
Unani formulation may be considered as non-inferior 
to control drug in the management of eczema.  
The Figures 2 and 3 show the response of the Unani 
formulation on eczema.  
In this study, the local and systemic safety of the 
test and control drugs was assessed. It was observed 
that the Unani formulation was tolerated well and 
found safe. The test drug showed no local and 
systemic adverse effect and toxicity during the 
course of the therapy. Poor response of the  
Unani formulation was observed after 6 weeks of 
treatment in three participants only. In addition, the 
control drug clobetasol propionate was also tolerated 
well by all the participants in the control group.  
The control drug demonstrated no local and systemic 
adverse effect till the end of 6 weeks therapy.  
In this group, three participants did not show 
response to the control drug, too. When compared to 
baseline, the haematological and biochemical 
parameters did not change after 6 weeks of treatment 
in both the groups. 
Discussion 
This study revealed that the Unani formulation was 
effective in reducing symptoms and signs of eczema. 
Our study demonstrated that the Unani formulation 
MSK alleviated the symptoms itching, exudation  
and cracking and the signs papules, erythema, 
lichenification, dryness and localized swelling at 6 
weeks of treatment compared to baseline. The 
efficacy exhibited by MSK might be possible due to 
medicinal properties of the individual constituents of 
MSK. Mom Safaid (Pure Wax), a good murakhkhi 
(emollient) and jali (detergent) drug may be 
responsible for the improvement in itching and 
dryness of the lesion18-19. The drugs Kafoor 
(Cinnamomum camphora), Roughan-e-gul (Oil of 
Rosa damascena), Safedab (Zinc oxide) and Safedi 
Baiza (Egg albumin) are known to have musakkin 
(anodyne) property might also be responsible in 
reducing itching21–24. It was observed that MSK 
resolved papules and erythema in a significant 
number of the participants. This effect of the 
formulation may be attributed to the muhallil 
(resolvent) property of Mom Safaid, Raughan-e-gul 
and Murdarsang20,22,25. The drugs Raughan e gul, 
Murdarsang and Safedab are mudammil-e- qurooh 
(cicatrizant/healing agent) which may have acted 
synergistically to heal papules and erythema22,26. The 
Unani formulation showed improvement in exudation 
in the study. This effect of the formulation may be 
attributed to the jali (detergent) action of Mom safaid, 
dafi’-i-ta‘affun (antiseptic) property of Murdarsang 
and Kafoor and mujaffif-i- ratoobat (desiccant) action 
of Safedab20-23,27. It was also observed that Unani 
formulation was effective in the alleviation of skin 
cracking. The possible reason for this effect of the 
Unani formulation might be due to murakhkhi 
(emollient) action of Mom safaid, Raughan-e-gul, 
munbit-e-laham (muscle grower) properties of 
Murdarsang and Safedab18,19,22,23. The drugs with 
emollient potential had been found effective in 
reducing symptoms of eczema in several clinical 
studies12,17. The Unani formulation also reduced 
localized swelling on the eczematous lesion. Mohallil 
(resolvent) action of Mom safaid, Raughan-e-gul, 
Murdarsang and Kafoor might be responsible for this 
effect of the Unani formulation20,22,27. This study also 
showed that the Unani formulation was effective in 
the improvement of lichenification which might be 
attributed to the mulattif (demulcent), murakhkhi 
(emollient) and mohallil (resolvent) actions of Mom 
 
 




Fig. 3 — After treatment 
 




safaid and mohallil (resolvent) action of Raughan-e-
gul and Murdarsang20,22,23. 
Clinical efficacy of some Unani formulations in 
eczema had been reported in a few studies. Nawab  
et al2 reported that topical application of a non-
pharmacopoeial formulation alleviated itching, 
erythema and papules in eczematous lesions after  
42 days of treatment. The control drug clobetasol 
propionate demonstrated efficacy in the reduction of 
itching, exudation, erythema and lichenification in the 
control group. The similar observation was reported 
in another clinical study conducted by Mayur Claria 
et al that clobetasol propionate was found to be 
responsive to the manifestations of chronic eczema 
and showed significant improvement in reduction in 
the degree of inflammation and itching28. 
There were several limitations in this study. The 
study was conducted on a small sample size (n=30 
each group), the duration of protocol therapy was very 
short and the time period for completion of the study 
was two years. The study was meant for academic 
purpose. So, there was the limitation of the funds, too.  
 
Conclusion 
This clinical study assessed and compared the 
efficacy and safety of topical Unani formulation 
Marham Safeda Kafoori (MSK) against Clobetasol 
Propionate. The findings of the study suggested that 
the Unani formulation was not inferior to Clobetasol 
propionate in terms of percentage of reduction in 
itching, dryness, erythema, oozing/exudation, scaling, 
excoriation and lichenification. This study was the 
first attempt to conduct a clinical trial of Unani 
formulation versus allopathic medicine Clobetasol 
propionate, which had already been found effective  
in the management of eczema. The outcome 
demonstrated in the study that the Unani formulation 
could be a promising drug for eczema. The leads in 
the study could be utilized to design another study 
with a large sample size to establish the efficacy of 
MSK in the management of eczema. Although this 
formulation has been used as a therapeutic for eczema 
for a long time, the efficacy and safety of the 
formulation have been in question before the 
scientific community due to lack of any clinical study 
demonstrating the efficacy of MSK. This study 
revealed that the Unani formulation MSK was safe 
and effective. There was no adverse effect reported 
during the study. It is, therefore, concluded that the 
Unani formulation MSK may be used as a safe and 
effective drug for treating eczema. 
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